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Abstract
Background: Our earlier work in the ultrasonograpy of localized scleroderma (LS) suggests that altered levels of 
echogenicity and vascularity can be associated with disease activity. Utrasound is clinically benign and readily 
available, but can be limited by operator dependence. We present our efforts to standardize image acquisition and 
interpretation of pediatric LS to better evaluate the correlation between specific sonographic findings and disease 
activity.
Methods: Several meetings have been held among our multi-center group (LOCUS) to work towards standardizing 
sonographic technique and image interpretation. Demonstration and experience in image acquisition were 
conducted at workshop meetings. Following meetings in 2007, an ultrasound measure was developed to standardize 
evaluation of differences in echogenicity and vascularity. Based upon our initial observations, we have labeled this an 
ultrasound disease activity measure. This preliminary measure was subsequently evaluated on over 180 scans of 
pediatric LS lesions. This review suggested that scoring levels should be expanded to better capture the range of 
observed differences. The revised levels and their definitions were formulated at a February 2009 workshop meeting. 
We have also developed assessments for scoring changes in tissue thickness and lesion size to better determine if 
these parameters aid evaluation of disease state.
Results: We have standardized our protocol for acquiring ultrasound images of pediatric LS lesions. A wide range of 
sonographic differences has been seen in the dermis, hypodermis, and deep tissue layers of active lesions. Preliminary 
ultrasound assessments have been generated. The disease activity measure scores for altered levels of echogenicity 
and vascularity in the lesion, and other assessments score for differences in lesion tissue layer thickness and changes in 
lesion size.
Conclusions: We describe the range of sonographic differences found in pediatric LS, and present our efforts to 
standardize ultrasound acquisition and image interpretation for this disease. We present ultrasound measures that may 
aid evaluation of disease state. These assessments should be considered a work in progress, whose purpose is to 
facilitate further study in this area. More studies are needed to assess their validity and reliability.
Background
Localized scleroderma (LS) is the most common form of
scleroderma in the pediatric age range. For both systemic
sclerosis and LS, there is an initial inflammatory phase
followed by the replacement of normal tissue structures
by abnormal collagen [1]. Although scleroderma refers to
hardening of the skin, pediatric LS often affects deeper
tissue, including muscle, bone, and some internal organs
[2]. Because active disease can persist for years, growing
children are at risk for major morbidity including joint
contractures, limb length discrepancy, and facial atrophy
[3,4].
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There are no available laboratory markers or validated
measures for monitoring disease activity in localized scle-
roderma [4]. Disease activity is usually defined as the
level or severity of reversible disease manifestations,
while damage is defined as irreversible, accumulated
changes from prior active disease [5]. Monitoring disease
activity can improve patient management, as increased
activity may signal a need for increased or intensified
treatment, while a sustained decrease may indicate that
treatment can be reduced.
Among the different imaging modalities available to
evaluate LS, ultrasound shows great promise for aiding
clinical assessment of LS disease activity. Several groups
have reported that changes in dermal thickness and level
of echogenicity correlate with disease activity [6-8]. We
have found these alterations also occur in deeper tissue
layers such as hypodermis and muscle. Moreover, we
have found a range of vascularity differences in the lesion.
In some patients, clinical improvement was associated
w i t h  l o s s  o f  h y p e r e m i a ,  a n d  w o r s e n i n g  w i t h  i n c r e a s e d
hyperemia and hyperechogenicity [9,10].
Studies by other groups of LS and other diseases, where
concurrent histological and ultrasound studies were per-
formed, have shown that hypoechogenicity is associated
with tissue edema, while hyperechogenicity is associated
with infiltration of normal tissue by inflammatory cells,
fat cells, or connective tissue [11-14]. Histological studies
have found tortuous and enlarged vessels, disturbed vas-
cular architecture, and neovascularization in localized
scleroderma lesions [15,16]. Older lesions can show a
reduced number of blood vessels because of replacement
of normal structures by fibrosis [1]. Increased blood flow
has also been detected in active lesions by laser Doppler
flowmetry, and suggested by the increased temperature
detected in active lesions by thermography [17,18].
Although many studies in several rheumatic diseases
have shown ultrasound to be more sensitive than clinical
evaluation, its use has been limited because both image
acquisition and interpretation are operator dependent.
There are no standards for most assessed features making
image interpretation potentially subject to great variabil-
ity between readers. To aid standardization of image
interpretation, scoring measures have been generated for
sonographic evaluation of different diseases. In rheuma-
toid arthritis, groups have proposed grading the observed
echogenicity features of effusions and synovitis on a 0 to
3 semiquantitative scale (0 is no abnormality, 1 mild or
minimal, 2 moderate, and 3 marked or extensive)[19,20].
Similarly, semiquantitative scoring of power Doppler sig-
nal from imaged joints has been proposed [19], with good
agreement found between semiquantitative (0 to 3 scale)
and quantitative scoring (based upon pixel count) in one
study [21].
In other diseases, groups have proposed grading the
level of echogenicity. For evaluating patients with neuro-
muscular, primary myopathy, and/or inflammatory mus-
c l e  d i s e a s e ,  H e c k m a t t  e t  a l  p r o p o s e d  s c o r i n g  m u s c l e
echogenicity on a 1 to 4 semiquantitative scale; good cor-
relation was found between the level of muscle echoge-
nicity and the severity of the muscle biopsy pathology
[22]. Scoring the level of echogenicity of the parotid gland
and breast tissue masses has also been suggested [23,24].
As echogenicity level, vascularity, and tissue thickness
vary across anatomic sites and between individuals [14],
it is important to select appropriate comparison sites or
standards when determining if the observed signals are
abnormal. For Sjogren's syndrome, parotid echogenicity
was compared to thyroid echogenicity, and for muscle
diseases, muscle echogenicity was compared to bone
[22,23]. Because LS, by definition, affects a limited region
of the body, this disease may be particularly suitable for
evaluation by ultrasound as each patient can serve as his
or her own control. We evaluate the LS lesion in compar-
ison to an uninvolved focus, ideally the normal contralat-
eral site, to enable accurate assessment of changes in
these parameters.
We have formed a multi-center, multi-disciplinary
group, LOCUS (Localized scleroderma Clinical and
Ultrasound Study group) that has been working to
develop disease assessment tools for LS. The member
sites are predominantly based in CARRA (Childhood
Arthritis and Rheumatology Research Alliance), a North
American pediatric rheumatology research alliance. To
facilitate standardization of image acquisition for local-
iz ed  s c l e r od e r m a,  w e  h a v e  h e l d  w o r ks h o p  m ee t i n gs  t o
allow review and standardization of technique. To stan-
dardize image interpretation, we have generated scoring
measures for evaluating differences in echogenicity, vas-
cularity, and tissue thickness based upon our review of
over 180 lesion scans from 21 patients. These measures
should be considered a work in progress, whose purpose
is to facilitate evaluation of the usefulness of ultrasound
for LS. Further work is needed to evaluate the validity and
reliability of these measures, and to identify which
parameters and scoring levels are most helpful for patient
care.
Methods
Standardization of image acquisition carried out
Two meetings were held at HUMC in 2007 (5/11/07, 7/
22/07) to demonstrate image acquisition, and allow
LOCUS radiologists and sonographers to review LS
images, and practice image acquisition on patient volun-
teers. A preliminary technique protocol was developed by
MSL, AM, and SCL. This protocol was reviewed and
modified at the Feb 21-24, 2009 meeting, with demon-Li et al. Pediatric Rheumatology 2010, 8:14
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strations and supervised image acquisition sessions on
patient volunteers over three days. Collected images from
these sessions were jointly reviewed to enable correction
of any technique errors, followed by additional demon-
stration and practice sessions. Dr. Liebling, Ms. Kornyat,
and Mr. Mohanta were primary instructors for these ses-
sions. During these meetings, all participants used Acu-
son Sequoia 512 machines, with linear-array transducers
and frequencies ranging from 8 to 15 MHz, to acquire
images.
US imaging protocol
The clinicians specify which site(s) to image on the
patient. Depending upon the transducer head size and
lesion size, only a portion of large lesions may be able to
be evaluated in a given scan. For large lesions, the clini-
cian identifies the portion of the lesion she thinks is most
active as the area to be imaged.
Ultrasound images are acquired using linear transduc-
ers, with preset software parameters for small parts, and
frequencies ranging from 8 to 15 MHz. Because the fre-
quencies used do not allow discrimination of the epider-
mis, we use the term dermis to refer to the combined
epidermis and dermis. The operator chooses the highest
frequency that allows adequate penetration; lower fre-
quencies may be needed to image the deeper tissue lay-
ers.
Identifying sonographic changes in the involved site is
accomplished by comparing both echogenicity and color
Doppler signal to a corresponding normal site. For a uni-
lateral lesion, the unaffected contralateral site is used for
comparison. Both the lesion and normal control site
images are viewed simultaneously on a dual image. The
transducer is held perpendicular to the skin, the settings
are maintained between the involved and control side,
and great care is taken to match underlying landmarks.
Focal zones are placed to optimize visualization of the tis-
sue layer, and multiple zones are used for multiple layers.
A thick layer of ultrasound gel is applied to improve near
field visibility and avoid tissue compression, which would
alter measurements of tissue thickness, echogenicity, and
vascularity [25]. Gel is felt to be superior to a stand-off
pad because of its ease of application and applicability on
all imaging locations including the face and other non-
flat surfaces. The layer of gel above the lesion and control
site should be visible on the monitor.
Echogenicity differences are evaluated from grey scale
images, and vascularity differences from standard color
Doppler images. The sensitivity of the color Doppler is
maximized by setting parameters to detect low flow. In
addition, the scale is minimized until noise is reached and
then raised until a visibly acceptable signal to noise ratio
is reached. This typically ranges from 0.005 and 0.015.
We consider each discrete color Doppler signal to repre-
sent an individual blood vessel, and refer to the color
Doppler signal as indicative of vascularity in this paper. In
a typical lesion scan, 9 to 20 grey scale and color Doppler
dual images are acquired.
Standardization of image interpretation
During the 2007 LOCUS meetings, radiologists, sonogra-
phers, and clinicians reviewed ultrasound images
acquired from 8 LS patients followed at Hackensack Uni-
versity Medical Center (HUMC), comparing active to
inactive patients. A preliminary ultrasound disease activ-
ity measure was generated towards the end of 2007 with
the intent of capturing the range of observed differences
and facilitating more consistent image interpretation. All
subsequent HUMC LS patient scans collected from 1/08
to 2/09 were evaluated by MSL and SCL using this pre-
liminary measure. Sixteen patients had ultrasound scans
acquired on 51 separate dates between 1/08 to 2/09, with
between one to six lesions or portions of lesions imaged
per patient scan date. Approximately 90 of the scans
acquired during this time were considered to be of active
lesions, and 55 of inactive or minimally active lesions.
Most of the scans acquired prior to this time (> 80) were
also reviewed with this measure. Overall, 21 pediatric LS
patients had ultrasound studies between 10/05 to 2/09,
with all scans acquired on Acuson Sequoia 512 machines
using linear-array transducers. Seven of the patients had
circumscribed morphea, six had linear scleroderma, six
had mixed morphea (both circumscribed morphea and
linear scleroderma), one had generalized morphea, and
one had pansclerotic morphea. From 2005 thru 2/09, the
technique for acquiring images evolved to enable more
consistent image quality. For our assessment of the devel-
oped measure, we only evaluated scans that were consid-
ered to have satisfactory technical quality. Similarly, only
scans and images that had satisfactory technical quality
were collected for group review at the February 2009
meeting.
At the February 21-24, 2009 meeting, LOCUS radiolo-
gists and sonographers reviewed over 20 LS scans plus
additional dual images from multiple other scans. The
meeting began with a review of the previously generated
ultrasound disease activity measure, and included exam-
ples from HUMC LS patient scans of the scoring levels of
each parameter of the measure. Additional patient images
were then reviewed that varied between each other in
observable degree of echogenicity or color Doppler dif-
ferences, but would still be scored at the same level
according to the developed measure. There was uniform
consensus that scoring levels should be expanded to bet-
ter capture the observed range of differences. The group
agreed to expand color Doppler scoring to include
decreased signal (-1), and broaden scoring of increased
signal from 1 to 2 to 1 to 3. Scoring of echogenicity differ-Li et al. Pediatric Rheumatology 2010, 8:14
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ences was expanded to include decreased echogenicity.
Increased echogenicity scoring was expanded from 1 to 2
to 1 to 3 for the hypodermis layer only as the greatest
range of difference was seen in this layer. There was less
agreement among the group members on how to
describe the different scoring levels, especially for vascu-
larity. Several definitions were proposed, reviewed
against different images, and through repeated discus-
sions, modified until uniform consensus was achieved.
MSL went through scoring of two patient scans with the
group, and then each group member individually scored
an additional two scans. MSL led a group review of the
scoring of the second set of scans; individuals were asked
how they scored the different parameters to assess the
uniformity in scoring and to comment if they did not
agree. The various group members reported good consis-
tency in scoring these two scans; however these scores
were not saved or formally analyzed. A reliability of scor-
ing study was conducted during the remainder of the
meeting, with each member scoring the same set of 17
scans provided to them in a random order. The results of
that study will be reported at a later time. The group also
defined scoring levels for evaluating tissue thickness dif-
ferences and monitoring changes in lesion size. This
study was approved by the HUMC institutional review
board and is endorsed by CARRA.
Results and Discussion
Development of the Disease activity measure
Our earlier work suggested that altered echogenicity and
vascularity signals in ultrasound scans of localized sclero-
derma patients can be associated with disease activity
[9,10]. To better assess the correlation between these sig-
nals and disease activity, the LOCUS ultrasound group
has been working to standardize interpretation of the
observed differences. A semiquantitative scoring mea-
sure was developed following review of patient images at
meetings in 2007. This measure was evaluated on subse-
quently collected patient scans, and modified during the
February 2009 meeting. This ultrasound disease activity
measure (Appendix 1) reflects the observed range of find-
ings to date; scoring levels were based on group consen-
sus of readily identifiable differences in sonographic
echogenicity and/or vascularity. For vascularity, we score
for observed differences in both number and size of dis-
crete color Doppler signals. A greater weight is given to
larger color Doppler signals as they may represent the
enlarged or tortuous vessels seen in histological studies of
lesions [15]. In addition, we score for relative area of color
Doppler signal; this type of scoring was also used in a
rheumatoid arthritis activity scoring measure [26].
Each tissue layer: dermis, hypodermis, and deep tissue
(i.e., muscle, breast glandular tissue, tendon), is scored
separately. The measure scores for the greatest observed
difference between the lesion and normal tissue layer.
The scored differences do not need to be evenly distrib-
uted in the evaluated tissue layer, and may be confined to
a limited portion of the lesion. The scored echogenicity
and vascularity differences must be seen in at least two
dual images from a given scan to be sure that they accu-
rately reflect the sonographic changes of the lesion. If a
given difference is not seen in two images, then the indi-
vidual scores of two separate dual grey scale images, or
three separate dual color Doppler images, are averaged
for scoring echogenicity or vascularity, respectively. The
cumulative disease activity score is determined by sum-
ming the absolute value of the individual parameters.
This yields a range from 0 to 15 (maximum echogenicity
score of 6, maximum vascularity score = 9, Appendix 1).
Further study is needed to determine if a -1 score for
echogenicity and/or vascularity has different significance
for disease activity than a +1 signal. It may be that a -1
vascularity score, for example, represents loss of normal
vasculature secondary to fibrosis and is therefore more
reflective of late stage changes or damage than activity.
The largest range of echogenicity differences was seen
in the hypodermis and smallest in the dermis; echogenic-
ity differences are scored on a -1 to 1 range for dermis, -1
to 3 range for hypodermis, and -1 to 2 range for deep tis-
sue (Appendix 1). A score of -1 represents hypoechoge-
nicity, 0 isoechogenicity, and positive numbers
hyperechogenicity of the lesion relative to the normal tis-
sue layer. A hypodermis echogenicity score of 3 was
defined as echogenicity of the hypodermis equal to or
greater than that of the normal dermis. To aid scoring of
lower levels of echogenicity, the scorer can compare with
visual examples such as those in Figures 1 to 3.
Figures 1, 2, 3 show examples of different echogenicity
scoring levels. The lesion dermal echogenicity is
increased compared to normal dermis in Figures 2 and 3
(dermal echogenicity score of 1). Figure 1 shows a mild
i n c r e a s e  i n  h y p o d e r m a l  e c h o g e n i c i t y  ( s c o r e  o f  1 )  i n  a
patchy distribution, while Figures 2 and 3 show a more
uniform increase in hypodermal echogenicity. A moder-
ate increase in hypodermal echogenicity is seen in Figure
2 (score of 2), and a marked increase in Figure 3 (score of
3). Figure 1 shows a decrease in lesion muscle (deep tis-
sue) echogenicity compared to the normal muscle (score
of -1), while Figure 2 shows a mild increase in muscle
echogenicity (score of 1) in a patchy pattern.
Vascularity differences are scored on a -1 to 3 range for
all tissues, where 0 represents no difference in color Dop-
pler signal level between the lesion and normal site, and is
defined as the range in color Doppler signal between -1
and 1. A score of -1 represents at least two fold fewer
color Doppler signals in the lesion compared to the nor-
mal site, 1 represents up to two fold more color Doppler
signals or one more large color Doppler signal in theLi et al. Pediatric Rheumatology 2010, 8:14
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lesion than normal site, and 2 and 3 represent further
increases in the lesion color Doppler signal level com-
pared to the normal site (Appendix 1). The maximum
score of 3 requires at least four more large color Doppler
signals, or an area of color Doppler signal involving at
least 20% more of the lesion tissue layer, compared to the
normal layer.
Figures 4, 5, 6, 7 show examples of different vascularity
scoring levels. In Figure 4, there are similar numbers of
small color Doppler signals between the lesion and nor-
mal hypodermis, and one large color Doppler signal in
the lesion giving a hypodermal vascularity score of 1. In
Figure 5, there are fewer color Doppler signals in the
lesion compared to normal hypodermis (hypodermal vas-
cularity score of -1), but more color Doppler signals in
the lesion muscle (deep tissue vascularity score of 2). The
same maximum vascularity score of 3 is given to lesion
tissue layers in Figures 6 and 7, with this score achieved
by number of large color Doppler signals in Figure 6, and
by surface area of color Doppler signal in Figure 7.
Tissue thickness and lesion size assessments
Although several studies have reported that changes in
dermal thickness are associated with changes in disease
state (worse vs improved [6-8]), we have not found an
obvious association between dermal, hypodermal, or
deep tissue thickness changes and disease activity in our
patients. In both active and inactive lesions, the lesion tis-
sue layer was usually thinner than or comparable in thick-
ness to the normal layer. Tissue thickening was seen in
some lesions, which might represent edema for newer
lesions and fibrosis for older lesions. We have, therefore,
decided to evaluate tissue thickness changes separately
from echogenicity and vascularity changes to better
determine the relationship between thickness changes of
each tissue layer and disease activity (Appendix 2). It may
Figure 1 14 year old girl with linear scleroderma affecting her left arm; portion shown is from her upper arm. She has chronic atrophy from 
long standing disease (11 years), with persistent signs of disease activity including erythema and pruritis. Ultrasound shows varying patterns of echo-
genicity differences in the lesion, with no difference found in the dermis (dermis echogenicity = 0), mildly increased echogenicity in the hypodermis 
in a patchy pattern (hypodermis echogenicity = 1), and decreased echogenicity in the muscle (deep tissue echogenicity = -1). Ultrasound allows facile 
measurement of tissue thickness. Cursors were placed at tissue boundaries, using the highest point of the humeral bone as a landmark for the mea-
surements. The lesion dermis is thinner than the normal dermis (measurement 2 (0.14 cm) vs 1 (0.21 cm), respectively; dermis tissue thickness score 
1). The lesion hypodermis is mildly thicker than the normal hypodermis (measurement 4 (0.82 cm) vs 3 (0.75 cm), respectively; hypodermis tissue thick-
ness score -1). The lesion muscle is thinner than the normal muscle (measurement 6 (0.93 cm) vs 5 (1.38 cm), respectively; deep tissue tissue thickness 
score 2). B = bone, D = dermis, H = hypodermis, and M = muscle. Arrowheads indicate boundaries of dermis, while arrows indicate boundaries of 
hypodermis and muscle. Large tick marks on x and y axis = 1 cm.Li et al. Pediatric Rheumatology 2010, 8:14
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also be that monitoring changes in tissue thickness over
time, rather than simply the presence of tissue thickening
or thinning, will aid disease activity assessment.
Tissue thickness differences between the lesion and
normal site are scored separately for each observable tis-
sue layer, with scoring including both thickening (-1) and
thinning (ranging from 1 to 3). The scoring range is great-
est for the hypodermis because the largest variation was
seen in this layer, ranging from mild to complete loss of
the hypodermal fat (Figure 1). Further study is needed to
learn if thickening and thinning are equivalent in order to
determine if the individual tissue layer thickness scores,
Figure 2 17 year old girl with generalized morphea that began over 13 years earlier. She has lesions on her back, abdomen, arms, and leg. Most 
lesions show dyspigmentation and mild tissue loss, but her back lesions have increased warmth. Ultrasound of a back lesion shows thinning of the 
dermis and hypodermis, and an increase in lesion dermal echogenicity (dermis echogenicity = 1). There are highly echogenic horizontal bands in the 
hypodermis layer of both the normal and lesion hypodermis layers. The echogenicity of these bands is increased in the lesion, as is the base level of 
hypodermal echogenicity (hypodermis echogenicity = 2). The lesion muscle shows a patchy increase in echogenicity compared to the normal muscle 
(deep tissue echogenicity = 1). Arrowheads indicate boundaries of dermis, while arrows indicate boundaries of hypodermis and muscle.
Figure 3 14 year old boy with circumscribed deep morphea of the infraorbital region for 2 years. His lesion has shown deeper pigmentation 
changes and recent increased tissue loss. There is marked thinning of the hypodermis layer. The echogenicity of the hypodermis is markedly increased, 
and greater than the echogenicity of the normal dermis (hypodermis echogenicity = 3). The echogenicity of the lesion dermis is also increased (dermis 
echogenicity = 1). D = dermis, H = hypodermis. Arrowheads indicate boundaries of dermis, while arrows indicate boundaries of hypodermis.Li et al. Pediatric Rheumatology 2010, 8:14
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or their absolute values, should be added together. Mea-
surements are obtained at the greatest difference in thick-
ness compared to the normal site. Great care is taken to
insure the underlying landmarks such as muscle planes
and bone are comparable from side to side (Figure 1). If
no sonographically distinguishable landmark is present,
external landmarks, such as distance from a joint are used
for determination of transducer placement. Measure-
ments are obtained either at the time of imaging acquisi-
tion or when viewing subsequently (Figure 1).
Figure 4 15 year old girl with linear scleroderma of her left leg that has progressed over the past three years. Her calf lesion shows erythema, 
warmth, and continuing tissue loss. Ultrasound shows an increase in lesion hypodermal vascularity; there are a few small color Doppler signals in both 
the lesion and normal hypodermis, and one large color Doppler signal in the lesion hypodermis (hypodermal vascularity = 1). D = dermis, H = hypo-
dermis. Arrowheads indicate boundaries of dermis, while arrows indicate boundaries of hypodermis.
Figure 5 15 year old girl with over an 8-year history of localized scleroderma. She initially presented with linear scleroderma of one hand that 
extended up her arm. There has been recent extension of this lesion to her upper back, and circumscribed morphea lesions have developed on her 
chest and thigh. Ultrasound image shown is of her upper arm, which had chronic atrophy and hyperpigmentation, but also mild erythema. There is 
increased vascularity in the lesion muscle, with over 10 discrete color Doppler signals in this layer versus none in the normal muscle. The deep tissue 
vascularity is scored as 2 because there are over two-fold more color Doppler signals in the lesion compared to normal; the vascularity is not scored 
as 3 because all of the lesion color Doppler signals are of a similar small size. The normal hypodermis has over two-fold more color Doppler signals 
than the lesion in this image, giving a lesion hypodermal vascularity score of -1. D = dermis, H = hypodermis, and M = muscle. Arrowheads indicate 
boundaries of dermis, while arrows indicate boundaries of hypodermis.Li et al. Pediatric Rheumatology 2010, 8:14
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We will also evaluate interval changes in overall lesion
size in comparison to disease activity. Here, we define
lesion size as the area of complete hypodermal fat loss.
This lesion size score is, therefore, only applicable in a
subset of patients, namely those who have a discretely
m e a s u r a b l e  a r e a  o f  h y p o d e r m a l  f a t  l o s s .  T h e  l e s i o n
boundaries must be accessible to ultrasound, so the size
of lesions involving the scalp, near the eye or nose, or
similar locations is not obtainable. The maximum length
and maximum orthogonal width are measured; if the
lesion size is smaller than the size of the transducer head,
the length and width can be directly measured on the
viewing monitor. In this case, single rather than dual
images can be acquired as shown in Figure 8. If the lesion
is greater than the transducer head, then the boundaries
of complete hypodermal loss are identified sonographi-
cally, marked on the patient with ink, and size measured
with a tape measure. Both worsening (increase in one or
Figure 6 6 year old girl with linear scleroderma of her calf for the past two years. The lesion is warm and mildly violaceous. There is loss of hy-
podermal fat in the lesion (left side of lesion image). The lesion muscle layer has increased vascularity with at least 4 more large color Doppler signals 
on the lesion side compared to the normal muscle (deep tissue vascularity = 3). The Doppler signal seen on the left hand side in the normal hypoder-
mis layer is artifact. B = bone, D = dermis, H = hypodermis, and M = muscle. Arrowheads indicate boundaries of dermis, while arrows indicate bound-
aries of hypodermis and muscle.
Figure 7 6 year old girl with a four year history of linear scleroderma of her left arm and hand. Her lesion has extended to her upper back, and 
she has new lesions on her face and chest. The imaged area is the volar surface of hand above 5th metacarpal bone, which shows chronic atrophy 
including shortening of this portion of her hand, but no signs of activity. The patient complained of pain in this area. There is abundant color Doppler 
signal in both the normal and lesion area, but more vascularity is seen in the lesion hypodermis and muscle layers. The lesion hypodermis shows a 
large area of contiguous color Doppler signal that encompasses at least 20% of the surface area of the imaged hypodermis (hypodermal vascularity 
= 3). There are 2 large color Doppler signals in the lesion muscle and none in the normal muscle, giving a deep tissue vascularity score of 2. B = bone, 
D = dermis, H = hypodermis, and M = muscle. Arrowheads indicate boundaries of tissue layers.Li et al. Pediatric Rheumatology 2010, 8:14
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both dimensions) and improvement (decrease in one or
both dimensions) can be documented with this score.
Conclusion
Localized scleroderma remains a challenging disease to
treat, with the potential for severe morbidity and disabil-
ity. There is no consensus on treatment, which ranges
from topical agents to phototherapy to systemic immu-
nosuppressive medications (reviewed in [4,27]). A great
need exists for sensitive disease assessment tools to better
evaluate treatment efficacy.
We and others have found that ultrasound can detect
several differences between active localized scleroderma
lesions and normal tissue. We have observed a range of
differences in tissue echogenicity between the lesion and
normal side, from hypoechoechogenicity to isoechoge-
n i c i t y  t o  h y p e r e c h o g e n i c i t y ,  w i t h  a c t i v e  l e s i o n s  m o r e
likely to show hypo- or hyperechogenicity than inactive
lesions. Similarly, we have observed a range of differences
in tissue vascularity between the lesion and normal side,
from decreased vascularity to no difference to marked
hyperemia. The ultrasound frequencies we use allow
detection of differences in the dermis, hypodermis, and
deep tissue layer, but not in the epidermis. For children,
evaluation of the hypodermis and deep tissue layers may
be especially important as disease often involves the
deeper tissues, putting the child at risk for major growth
disturbances.
As an initial step towards developing ultrasound as an
assessment tool for localized scleroderma, our group has
been working to standardize image acquisition and inter-
pretation for these patients. Training and practice imag-
ing sessions on patient volunteers were held to develop a
standard image acquisition protocol that we present here.
Joint reviews of patient images were held at meetings in
2007 and 2009, and led to consensus on scoring measures
to facilitate more consistent interpretation of alterations
in lesion echogenicity, vascularity, and tissue thickness. A
limitation of our study is that we did not have each radiol-
ogist and sonographer independently review images, but
only had a group review prior to discussions leading to
consensus. We also did not consider the radiologists' and
Figure 8 8 year old girl with linear scleroderma of her lower leg with a four year history of active disease. A single rather than dual screen 
image was obtained to allow measurement of lesion size. The boundaries of the area of complete loss of hypodermal fat were identified directly on 
the viewing monitor, with cursors placed at boundary points to determine the width of the area of fat loss (3.79 cm). B = bone, D = dermis, H = hypo-
dermis, and M = muscle. Arrowheads indicate boundaries of merged dermis and hypodermis, while arrows indicate boundaries of hypodermis and 
muscle.Li et al. Pediatric Rheumatology 2010, 8:14
http://www.ped-rheum.com/content/8/1/14
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sonographers' prior experience in evaluating ultrasound
images when working towards consensus. Our aim, how-
ever, was to standardize ultrasound acquisition and image
assessment within our group so that we could collectively
work to evaluate ultrasound assessment of localized scle-
roderma. These measures should be considered prelimi-
nary. Scoring levels were set based upon the observed
range of sonographic differences, and further study is
needed to evaluate their validity and reliability and deter-
mine clinically relevant scoring levels and changes. Once
valid and reliable tools are developed, clinical trials can
be conducted to work towards improved treatment and
outcome for these patients.
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Appendix 1: Ultrasound disease activity measure 
(U-DA)
Echogenicity Score
Dermis:
-1 = Decreased compared to normal site
0 = No difference compared to normal site
+1 = Increased compared to normal site
Hypodermis:
-1 = Decreased compared to normal site
0 = No difference compared to normal site
+1 = Some increase compared to normal site
2 = Moderate increase: echogencity > normal hypoder-
mis but < normal dermis signal
3 = Large increase: echogenicity similar to or > normal
dermis signal
Deep tissue (i.e., muscle, tendon, glandular)
-1 = Decreased compared to normal site
0 = No difference compared to normal site
+1 = Mild increase compared to normal site
2 = Moderate to large increase compared to normal site
Vascularity Score
0 = No difference compared to normal site (between 1
and decreased)
1 = Mild; lesion has 1 more larger vessel than normal
site
Or , if no or same number of larger vessels present,
then lesion has more
blood vessels then normal site (ratio of lesion to nor-
mal blood vessels >1x, ≤ 2x)
2 = Moderate; in between 1 and 3; lesion has 2 or 3
more larger vessels
compared to normal site. Or, if no or same number of
larger vessels
present, then lesion has >2x more blood vessels than
normal site
3 = Large; lesion has ≥ 4 larger vessels than normal site
Or, lesion has increased number and/or size of blood
vessels with increase involving at least 20% more of
tissue layer field area
-1 = opposite of 2; Normal site has ≥ 2 larger vessels or
>2x more blood vessels than lesion
Score each visualized layer separately. Not all lesions
have a deep tissue layer. Each parameter is scored for the
greatest level of difference that is seen in at least two sep-
arate dual images. The scored differences do not need to
be evenly distributed in the evaluated tissue layer. If a
given difference is not seen in two images, then the indi-
vidual scores of two separate dual grey scale images, or
three separate dual color Doppler images, are averaged
for scoring echogenicity or vascularity, respectively. Each
color Doppler signal is considered to represent a blood
vessel. Dermis represents both epidermis and dermis.
When there is complete loss of subcutaneous fat within
the hypodermis, the dermis and hypodermis are not visu-
ally separable; the layer superficial to a region of complete
h y p o d e r m a l  f a t  l o s s  i s  s c o r e d  a s  d e r m i s .  I n  t h i s  c a s e ,
hypodermal echogenicity is scored from hypodermis
directly adjacent to the site of complete loss. The absolute
values of the individual parameters are summed to deter-
mine the score, which ranges from 0 to 15.
Appendix 2: Tissue thickness and Lesion size scores
Tissue Thickness Score
Dermis
-1 = thickening
0 = none
1 = thinning
Hypodermis
-1 = thickening
0 = none
1 = mild thinning, <20%
2 = thinning ≥ 20% to 89%
3 = ≥ 90% thinning, or no fat
Deep Tissue
-1 = thickening
0 = none
1 = thinning <20%
2 = thinning ≥ 20%
Lesion Size Score
percentage change refers to a change in measured length
or width
-2 = decreased >25%
-1 = decreased 10-25%
0 = <10% change in size
+1 = increased 10-25%
+2 = increased >25%Li et al. Pediatric Rheumatology 2010, 8:14
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The tissue thickness score is determined by evaluating
the degree of tissue loss or thickening in the lesion der-
mis, hypodermis, and, if present, deep tissue layer, in
comparison to the normal tissue layers. Measurements
are obtained at the most abnormal thickness portion of
the lesion using landmarks such as a bone to aid identifi-
cation of the normal comparison site. Measurements can
be obtained at the time of imaging acquisition or during
subsequent review.
The lesion size score can only be used on lesions that
have a sonographically accessible area of complete loss of
subcutaneous fat. The maximum length and maximum
orthogonal width are measured; if the lesion size is
smaller than the size of the transducer head, the length
and width can be directly measured on the viewing moni-
tor. Otherwise, boundaries are identified by ultrasound,
marked on the patient's skin, and then measured with a
tape measure. Negative numbers indicate a decrease in
lesion width and/or length as would be seen with clinical
improvement, and positive numbers indicate an increase
in width and/or length as would be seen with disease flare
or worsening.
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